OmniAb, Inc.

Equities

OABI

US68218J1034

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-07-05 pm EDT 5-day change 1st Jan Change
3.82 USD +4.66% Intraday chart for OmniAb, Inc. +1.87% -38.09%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
OmniAb, Inc. Announces Board Changes CI
OmniAb, Inc.(NasdaqGM:OABI) added to Russell Microcap Growth Index CI
OmniAb, Inc.(NasdaqGM:OABI) added to Russell 2500 Growth Index CI
OmniAb, Inc.(NasdaqGM:OABI) added to Russell Small Cap Comp Growth Index CI
OmniAb, Inc.(NasdaqGM:OABI) added to Russell 3000E Growth Index CI
OmniAb, Inc.(NasdaqGM:OABI) added to Russell 3000 Growth Index CI
OmniAb, Inc.(NasdaqGM:OABI) added to Russell 2000 Growth Index CI
Omniab Insider Bought Shares Worth $1,059,840, According to a Recent SEC Filing MT
Earnings Flash (OABI) OMNIAB Reports Q1 Revenue $3.8M, vs. Street Est of $5.9M MT
OmniAb, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Transcript : OmniAb, Inc., Q1 2024 Earnings Call, May 09, 2024
OmniAb Insider Bought Shares Worth $1,167,750, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Gain Pre-Bell Thursday MT
OmniAb Swings to Q4 Loss, Revenue Declines MT
Earnings Flash (OABI) OMNIAB Posts Q4 Revenue $4.8M, vs. Street Est of $7.46M MT
Transcript : OmniAb, Inc., Q4 2023 Earnings Call, Mar 20, 2024
OmniAb, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
OmniAb, Inc.(NasdaqGM:OABI) added to NASDAQ Biotechnology Index CI
OmniAb, Inc. Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference CI
Omniab Insider Bought Shares Worth $1,010,000, According to a Recent SEC Filing MT
RBC Initiates OmniAb at Outperform With $6 Price Target, Says Stock Gives Exposure to Growth Potential of Monoclonal Antibody Therapies MT
Omniab Insider Bought Shares Worth $405,517, According to a Recent SEC Filing MT
Transcript : OmniAb, Inc. - Special Call
OmniAb, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (OABI) OMNIAB Posts Q3 Revenue $5.5M, vs. Street Est of $10.3M MT
Chart OmniAb, Inc.
More charts
OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.82 USD
Average target price
9.875 USD
Spread / Average Target
+158.51%
Consensus
  1. Stock Market
  2. Equities
  3. OABI Stock
  4. News OmniAb, Inc.
  5. Earnings Flash (OABI) OMNIAB Posts Q4 Revenue $4.8M, vs. Street Est of $7.46M